Compare Manulife Financial Corporation (MFC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs ResMed Inc. — how do they compare? Manulife Financial Corporation trades at $43.58 (market cap $69.26B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Manulife Financial Corporation is far larger — about 2.2× ResMed Inc.'s market cap, and Manulife Financial Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and ResMed Inc. for 51 Days on average.
| MFC | RMD | |
|---|---|---|
Market Cap | $69.26B | $31.78B |
Volume | 1,347,387 | 1,128,382 |
Sector | Financials | Health |
52-Week High | $44.77 | $277.88 |
52-Week Low | $31.64 | $182.82 |
Typical Hold Time | 119 Days | 51 Days |
Enterprise Value | $64.51B | $31.14B |
Dividend Yield | 3.27% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $42.12, down 1.89% today, with a bearish technical outlook despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and others highlight confidence, while analyst consensus remains positive with 57% buy ratings.
MFC presents a mixed outlook: strong operational performance and dividend yield support upside, but technical indicators signal near-term pressure. Key risks include debt levels and market volatility, while opportunities lie in Asia growth and reinsurance deals. The stock trades above the consensus price target of $34.24, suggesting cautious optimism with execution-dependent returns.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
